Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

including an amylin receptor agonist, with an IND filing anticipated by the end of 2025. Get comprehensive insights into Viking Therapeutics’ potential with InvestingPro’s detailed Research ...

Dual Amylin and Calcitonin Receptor Agonist ... and Viking will retain ownership of all global rights to VK2735. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused ...

Dual Amylin and Calcitonin Receptor Agonist ... on the Webcasts page of Viking's website for 30 days. About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

About Viking Therapeutics, Inc. Viking Therapeutics ... newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity ...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical ... The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists ...